Pascal Chanu

541 total citations
29 papers, 403 citations indexed

About

Pascal Chanu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Pascal Chanu has authored 29 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Pascal Chanu's work include CAR-T cell therapy research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Pascal Chanu is often cited by papers focused on CAR-T cell therapy research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Pascal Chanu collaborates with scholars based in France, Switzerland and United States. Pascal Chanu's co-authors include E. Niclas Jonsson, Ronald Gieschke, Norbert Frey, René Bruno, Jorge Grippo, Eric Snoeck, Karin Jorga, Jin Y. Jin, Marc Lavielle and Philippe Jacqmin and has published in prestigious journals such as Clinical Cancer Research, British Journal of Cancer and Pharmaceutical Research.

In The Last Decade

Pascal Chanu

28 papers receiving 383 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pascal Chanu France	13	137	98	73	68	67	29	403
Sven Mensing United States	12	113 0.8×	112 1.1×	58 0.8×	146 2.1×	33 0.5×	43	638
Alexandre A. Jácome Brazil	16	315 2.3×	51 0.5×	32 0.4×	88 1.3×	27 0.4×	45	574
Kinjal Sanghavi United States	11	205 1.5×	34 0.3×	21 0.3×	70 1.0×	35 0.5×	24	526
Jean‐François Ramée France	9	160 1.2×	76 0.8×	53 0.7×	42 0.6×	149 2.2×	15	460
Jo Ann Rinaudo United States	16	284 2.1×	224 2.3×	216 3.0×	188 2.8×	72 1.1×	27	692
Barbara J. Brennan United States	13	139 1.0×	164 1.7×	169 2.3×	100 1.5×	55 0.8×	41	530
Marie‐Aude Le Berre France	8	69 0.5×	88 0.9×	65 0.9×	57 0.8×	106 1.6×	17	435
Michael Li United States	12	168 1.2×	72 0.7×	72 1.0×	77 1.1×	29 0.4×	32	388
Peter N. Morcos United States	13	156 1.1×	271 2.8×	267 3.7×	90 1.3×	86 1.3×	37	597
Jian Zhu China	10	90 0.7×	78 0.8×	52 0.7×	76 1.1×	64 1.0×	32	401

Countries citing papers authored by Pascal Chanu

Since Specialization

Citations

This map shows the geographic impact of Pascal Chanu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal Chanu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal Chanu more than expected).

Fields of papers citing papers by Pascal Chanu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal Chanu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal Chanu. The network helps show where Pascal Chanu may publish in the future.

Co-authorship network of co-authors of Pascal Chanu

This figure shows the co-authorship network connecting the top 25 collaborators of Pascal Chanu. A scholar is included among the top collaborators of Pascal Chanu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascal Chanu. Pascal Chanu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tang, Alice, et al.. (2025). Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations. Clinical Pharmacology & Therapeutics. 118(1). 146–155.

Chan, Phyllis, Nathalie Gosselin, Mathilde Marchand, et al.. (2025). Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer. CPT Pharmacometrics & Systems Pharmacology. 14(4). 726–737. 2 indexed citations

Marchand, Mathilde, António Gonçalves, François Mercier, et al.. (2024). Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two‐stage approaches. CPT Pharmacometrics & Systems Pharmacology. 13(6). 1017–1028. 3 indexed citations

Li, Chi‐Chung, Brendan C. Bender, Justin Wilkins, et al.. (2024). A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma. Clinical Pharmacology & Therapeutics. 117(2). 465–474. 3 indexed citations

Vora, Bianca, et al.. (2024). Expanding the use of real‐world data through the development of user‐friendly tools to support drug development: Example of an organ impairment dashboard. Pharmacology Research & Perspectives. 12(4). e1239–e1239. 1 indexed citations

Bender, Brendan C., Chi‐Chung Li, Mathilde Marchand, et al.. (2024). Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma. Clinical and Translational Science. 17(6). e13825–e13825. 7 indexed citations

Zhu, Rui, Bianca Vora, Sujatha Menon, et al.. (2023). Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective. Clinical Pharmacology & Therapeutics. 114(4). 751–767. 18 indexed citations

Bruno, René, Pascal Chanu, Matts Kågedal, et al.. (2023). Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models. British Journal of Cancer. 129(9). 1383–1388. 13 indexed citations

Bruno, René, Mathilde Marchand, Kenta Yoshida, et al.. (2023). Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clinical Cancer Research. 29(6). 1047–1055. 13 indexed citations

10.

Jamalian, Samira, Michael Dolton, Pascal Chanu, et al.. (2023). Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB. CPT Pharmacometrics & Systems Pharmacology. 12(7). 1029–1042. 10 indexed citations

11.

Huang, Weize, Felix Stader, Phyllis Chan, et al.. (2022). Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors. Frontiers in Pharmacology. 13. 974423–974423. 6 indexed citations

12.

Kotani, Naoki, Justin Wilkins, Janet R. Wade, et al.. (2022). Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study. Cancer Chemotherapy and Pharmacology. 90(6). 511–521. 4 indexed citations

13.

Yoshida, Kenta, Justin Wilkins, Julia Winkler, et al.. (2021). Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients. The Journal of Clinical Pharmacology. 61(12). 1579–1591. 10 indexed citations

14.

Lü, Dan, Tong Lu, Leonid Gibiansky, et al.. (2020). Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma. Pharmaceutical Research. 37(12). 252–252. 13 indexed citations

15.

Shemesh, Colby S., Pascal Chanu, Kris M. Jamsen, et al.. (2019). Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. Journal for ImmunoTherapy of Cancer. 7(1). 314–314. 36 indexed citations

16.

Chanu, Pascal, Xiang Gao, René Bruno, Laurent Claret, & Lutz Harnisch. (2019). A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension. Journal of Pharmacokinetics and Pharmacodynamics. 46(5). 499–509. 2 indexed citations

17.

Claret, Laurent, Jenny Zheng, François Mercier, et al.. (2016). Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline. Cancer Chemotherapy and Pharmacology. 78(3). 605–610. 4 indexed citations

18.

Bruno, René, Lars Lindbom, Pascal Chanu, et al.. (2012). Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer. CPT Pharmacometrics & Systems Pharmacology. 1(12). 1–6. 15 indexed citations

19.

Chanu, Pascal, et al.. (2010). Population Pharmacokinetic/Pharmacodynamic Model for C.E.R.A. in Both ESA‐Naïve and ESA‐Treated Chronic Kidney Disease Patients With Renal Anemia. The Journal of Clinical Pharmacology. 50(5). 507–520. 13 indexed citations

20.

Rayner, Craig R., Pascal Chanu, Ronald Gieschke, Lauren Boak, & E. Niclas Jonsson. (2008). Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid. The Journal of Clinical Pharmacology. 48(8). 935–947. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact